Shanghai MicroPort Endovascular MedTech Full Year 2024 Earnings: Misses Expectations

Shanghai MicroPort Endovascular MedTech (SHSE:688016) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥1.21b (up 1.6% from FY 2023).
• Net income: CN¥502.1m (up 2.0% from FY 2023).
• Profit margin: 42% (in line with FY 2023).
• EPS: CN¥4.07.

The end of cancer? These 15 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Shanghai MicroPort Endovascular MedTech Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 5.9%. Earnings per share (EPS) also missed analyst estimates by 25%.

Looking ahead, revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Medical Equipment industry in China.

Performance of the Chinese Medical Equipment industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

It is worth noting though that we have found 2 warning signs for Shanghai MicroPort Endovascular MedTech (1 shouldn't be ignored!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.